Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer.
Piccart MJ, Klijn J, Paridaens R, Nooij M, Mauriac L, Coleman R, Bontenbal M, Awada A, Selleslags J, Van Vreckem A, Van Glabbeke M. Piccart MJ, et al. Among authors: nooij m. J Clin Oncol. 1997 Sep;15(9):3149-55. doi: 10.1200/JCO.1997.15.9.3149. J Clin Oncol. 1997. PMID: 9294478 Clinical Trial.
Vorozole (Rivizor): an active and well tolerated new aromatase inhibitor for the treatment of advanced breast cancer patients with prior tamoxifen exposure. Investigational Drug Branch of the European Organization for Research and Treatment of Cancer (EORTC) Breast Cancer Cooperative Group.
Paridaens R, Roy JA, Nooij M, Klijn J, Houston SJ, Beex LV, Vinholes J, Tomiak E, Van Vreckem A, Langenaeken C, Van Glabbeke M, Piccart MJ. Paridaens R, et al. Among authors: nooij m. Anticancer Drugs. 1998 Jan;9(1):29-35. doi: 10.1097/00001813-199801000-00003. Anticancer Drugs. 1998. PMID: 9491789 Clinical Trial.
EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer.
Hamilton A, Biganzoli L, Coleman R, Mauriac L, Hennebert P, Awada A, Nooij M, Beex L, Piccart M, Van Hoorebeeck I, Bruning P, de Valeriola D. Hamilton A, et al. Among authors: nooij m. Ann Oncol. 2002 Jun;13(6):910-8. doi: 10.1093/annonc/mdf157. Ann Oncol. 2002. PMID: 12123337 Free article. Clinical Trial.
Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European Organization for Research and Treatment of Cancer multicenter trial.
Biganzoli L, Cufer T, Bruning P, Coleman RE, Duchateau L, Rapoport B, Nooij M, Delhaye F, Miles D, Sulkes A, Hamilton A, Piccart M. Biganzoli L, et al. Among authors: nooij m. Cancer. 2003 Jan 1;97(1):40-5. doi: 10.1002/cncr.10914. Cancer. 2003. PMID: 12491503 Free article. Clinical Trial.
Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group.
Paridaens RJ, Dirix LY, Beex LV, Nooij M, Cameron DA, Cufer T, Piccart MJ, Bogaerts J, Therasse P. Paridaens RJ, et al. Among authors: nooij m. J Clin Oncol. 2008 Oct 20;26(30):4883-90. doi: 10.1200/JCO.2007.14.4659. Epub 2008 Sep 15. J Clin Oncol. 2008. PMID: 18794551 Free PMC article. Clinical Trial.
Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer.
Paridaens R, Dirix L, Lohrisch C, Beex L, Nooij M, Cameron D, Biganzoli L, Cufer T, Duchateau L, Hamilton A, Lobelle JP, Piccart M; European Organization for the Research and Treatment of Cancer (EORTC)- Investigational Drug Branch for Breast Cancer (IDBBC). Paridaens R, et al. Among authors: nooij m. Ann Oncol. 2003 Sep;14(9):1391-8. doi: 10.1093/annonc/mdg362. Ann Oncol. 2003. PMID: 12954578 Free article. Clinical Trial.
The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'.
Atalay G, Dirix L, Biganzoli L, Beex L, Nooij M, Cameron D, Lohrisch C, Cufer T, Lobelle JP, Mattiaci MR, Piccart M, Paridaens R. Atalay G, et al. Among authors: nooij m. Ann Oncol. 2004 Feb;15(2):211-7. doi: 10.1093/annonc/mdh064. Ann Oncol. 2004. PMID: 14760111 Free article. Clinical Trial.
An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes.
Awada A, Biganzoli L, Cufer T, Beex L, Lohrisch C, Batter V, Hamilton A, Nooij M, Piccart M. Awada A, et al. Among authors: nooij m. Eur J Cancer. 2002 Apr;38(6):773-8. doi: 10.1016/s0959-8049(01)00427-0. Eur J Cancer. 2002. PMID: 11937310 Clinical Trial.
Vorozole (R83842) in the treatment of postmenopausal advanced breast cancer: relationship of serum levels of vorozole and clinical results (a study of the EORTC Breast Cancer Cooperative Group).
Bruning PF, Bonfrer JM, Paridaens R, Nooij M, Klijn JG, Beex LV, Bruynseels J, Piccart MJ. Bruning PF, et al. Among authors: nooij m. Anticancer Drugs. 1998 Jun;9(5):419-25. doi: 10.1097/00001813-199806000-00008. Anticancer Drugs. 1998. PMID: 9660539 Clinical Trial.
56 results